Condition
Cryptococcal Meningitis
ClinicalTrials.gov condition label
Explore related research
Search across original and mapped recordsSearch results distinguish clinical terminology from original registry names. Shared trial participation does not imply treatment or approval.
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 23 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
23 shownPlatform Trial For Cryptococcal Meningitis (PLATFORM-CM)NCT06666322 · 2025-05-28
RECRUITINGOptimizing Care for Cryptococcal Antigenemia: Evaluation of Short Course Fluconazole and ART Timing Among CrAg+ Persons With Low TitersNCT07743593 · 2027-01-05
NOT_YET_RECRUITINGAmphotericin B for Non-HIV Cryptococcal Meningitis PatientsNCT06178627 · 2023-08-13
UNKNOWNPoint of Care Tests to Identify Opportunistic Infections in Advanced HIV Patients in Mexico CityNCT05685641 · 2023-04-01
UNKNOWNClinical Study of ABCD in the Treatment of Cryptococcal MeningitisNCT05471063 · 2022-08-22
UNKNOWNThree Induction Treatments on Cryptococcal MeningitisNCT04072640 · 2021-01-25
UNKNOWNClinical Effectiveness and Safety of Amphotericin B With Flucytosine-Fluconazole Therapy for Cryptococcal MeningitisNCT04532463 · 2020-10-01
COMPLETEDThe Lived Experience of Participants in an African Randomised TrialNCT04296292 · 2020-02-05
COMPLETEDAmB Dose for Cryptococcal MeningitisNCT04140461 · 2020-01-02
UNKNOWNDriving Reduced AIDS-associated Meningo-encephalitis MortalityNCT03226379 · 2016-04-23
COMPLETEDEfficacy of Intrathecal Administration of Liposomal Amphotericin B in Cryptococcal MeningitisNCT02686853 · 2016-01-01
UNKNOWNVietnam Cryptococcal Retention in Care Study - Version 2.1NCT03267407 · 2015-08-14
UNKNOWNVietnam Cryptococcal Retention in Care Study (CRICS) Federal Financial ReportNCT02955862 · 2015-06-01
COMPLETEDCryptoART Study: Decreasing Mortality Associated With Initiation of Antiretroviral Therapy in Sub-Saharan AfricaNCT02434172 · 2015-04-01
COMPLETEDAdjunctive Sertraline for the Treatment of HIV-Associated Cryptococcal MeningitisNCT01802385 · 2015-03-09
COMPLETEDClinical Outcomes of Cryptococcal Meningitis Among HIV-infected Patients in the Era of Antiretroviral TherapyNCT02098525 · 2013-11-01
COMPLETEDOperational Research for Cryptococcal Antigen ScreeningNCT01535469 · 2012-07-01
COMPLETEDStudy Evaluating Efficiency and Tolerance of High-dose Fluconazole Associated With Flucytosine as Induction Therapy for Cryptococcal Meningitis Associated With HIV in Sub-saharan AfricaNCT01715922 · 2012-05-01
UNKNOWNCryptococcal Optimal ART Timing TrialNCT01075152 · 2010-11-01
COMPLETEDHigh-Dose Fluconazole for the Treatment of Cryptococcal Meningitis in HIV-Infected IndividualsNCT00885703 · 2010-04-16
COMPLETEDOptimal Time to Start Antiretroviral Therapy in HIV-infected Adults With Cryptococcal MeningitisNCT00976040 · 2009-09-01
COMPLETEDEarly Versus Delayed Antiretroviral Therapy (ART) in the Treatment of Cryptococcal Meningitis in AfricaNCT00830856 · 2006-10-01
COMPLETEDAmphotericin Alone or in Combination With Fluconazole for AIDS-Associated MeningitisNCT00145249 · 2005-05-01
COMPLETEDCommon interventions
fluconazoleDRUG6Amphotericin BDRUG3flucytosineDRUG310-Week FluconazoleDRUG124-Week FluconazoleDRUG1Amphotericin B 0.5 mg/kg/day i.v. combined with flucytosine four times per day orally for the first 4 weeks.DRUG1Amphotericin B 0.7 mg/kg/day i.v. combined with flucytosine four times per day orally for the first 4 weeks.DRUG1Amphotericin B 1 mg/kg 1 week & Flucytosine 100 mg/kg 1 week followed by Fluconazole 1200 mg/day 1 weekDRUG1Amphotericin B Colloidal DispersionDRUG1amphotericin B deoxycholate (0.4-0.5mg/kg/d)DRUG1Amphotericin B-deoxycholate (0.7-1.0mg/kg/d)DRUG1Cryptococcal Lateral Flow Antigen testDIAGNOSTIC_TEST1Delayed ART InitiationDRUG1DREAMMOTHER1Early antiretroviral therapyOTHER1efavirenzDRUG1Fixed dose - Stavudine, lamivudine and NevirapineDRUG1Fixed dose - Stavudine, Lamivudine, NevirapineDRUG1Histoplasma Urine Antigen Lateral Flow Antigen testDIAGNOSTIC_TEST1Immediate ART InitiationDRUG1In-depth interviewsOTHER1Liposomal amphotericin BDRUG1lumbar puncturesPROCEDURE1nucleosideBIOLOGICAL1Oteseconazole - antifungal therapy 1DRUG1
Mapped drugs appearing in these trials
Shared trial participation only; not evidence of efficacy or approval.
Leading sponsors
University of Minnesota
4
National Hospital for Tropical Diseases, Hanoi, Vietnam
2
National Institute of Allergy and Infectious Diseases (NIAID)
2
University of Zimbabwe
2
ANRS, Emerging Infectious Diseases
1
Botswana-UPenn Partnership
1
David Boulware
1
First Affiliated Hospital of Zhejiang University
1
Huashan Hospital
1
Hui Bu
1
London School of Hygiene and Tropical Medicine
1
Mahidol University
1
National Institute of Respiratory Diseases, Mexico
1
Peking Union Medical College Hospital
1
Shanghai Public Health Clinical Center
1
Trial status mix
COMPLETED13
UNKNOWN8
NOT_YET_RECRUITING1
RECRUITING1
Phase mix
PHASE35
PHASE45
NA4
PHASE24
PHASE12
EARLY_PHASE11
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.